# JBCHEPHARM (JBCHEPHARM) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/jbchepharm

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹2,408.9
- Change: +0.00%
- As of: 2026-07-15
- 1D return: +0.00%
- 5D return: -1.09%
- 1M return: +9.57%
- Latest complete quarter: fy26_q4

## Faxioms Analysis

_As of 2026-09-18_

### Technical Outlook

As of September 18, 2026, JBCHEPHARM is trading at ₹2408.9, with a technical stance indicating strength across multiple timeframes. Daily, weekly, and monthly indicators suggest an uptrend, with the price trading above key moving averages like the 20-day Exponential Moving Average (EMA) and the 200-day Simple Moving Average (SMA) on the daily chart. The Supertrend indicator is also bullish across all observed timeframes. Recent market activity shows one neutral event in the last 30 days, with no downside or positive attention events. The stock is positioned within its recent trading range, closer to the upper bounds on longer-term views (87% of the 252-day range). Volatility is noted at 25% annualized, with a current drawdown of -4% and a maximum drawdown of -21% observed historically.

Key patterns observed include an Inside Bar on the monthly timeframe and an Outside Bar on the weekly timeframe, both active as of September 18, 2026. These patterns suggest potential for consolidation or a significant price move following the formation. The nearest resistance is identified at ₹2438.13 (1.21% away), followed by ₹2496.27 (3.63% away). Support is found at ₹2386.8 (0.92% away) and ₹2350.77 (2.41% away).

Investors should monitor the stock's interaction with the ₹2438.13 resistance level. A sustained move above this could signal further upside, while a break below the ₹2386.8 support level might indicate a short-term pullback. The presence of Inside and Outside Bar patterns suggests that a notable price movement could be imminent, making these levels critical watch points.

- The stock closed at ₹2408.9 on September 18, 2026, with bullish signals across daily, weekly, and monthly timeframes.
- The price is trading above key moving averages (20-day EMA, 50-day EMA, 200-day SMA) and the Supertrend indicator on the daily chart.
- Nearest resistance levels are ₹2438.13 and ₹2496.27, while support is located at ₹2386.8 and ₹2350.77.
- Active Inside Bar (monthly) and Outside Bar (weekly) patterns suggest potential for a significant price move.
- Watch for a break above ₹2438.13 for potential upside continuation or a break below ₹2386.8 for potential short-term weakness.

- Inside Bar
- Outside Bar

### News Context

J. B. Chemicals & Pharmaceuticals Limited's corporate structure underwent a significant change with its amalgamation into Torrent Pharmaceuticals Limited, which became effective from January 21, 2026. This integration was finalized following the National Company Law Tribunal's (NCLT) sanction of the Scheme of Amalgamation on July 6, 2026, with the certified order received on July 7, 2026. The company officially dissolved into Torrent Pharmaceuticals on July 8, 2026, after the certified copies of the order and scheme were filed with the Registrar of Companies, Ahmedabad. As part of the amalgamation process, July 17, 2026, was set as the record date for shareholders to determine their entitlement to Torrent Pharmaceuticals shares, with the exchange ratio set at 51 Torrent Pharma shares for every 100 J. B. Chemicals shares held. Separately, on July 7, 2026, J. B. Chemicals confirmed compliance with SEBI regulations regarding the dematerialization of securities for the quarter ending June 30, 2026.

- J. B. Chemicals & Pharmaceuticals Limited was amalgamated with and dissolved into Torrent Pharmaceuticals Limited, effective January 21, 2026, with the formal dissolution occurring on July 8, 2026.
- The National Company Law Tribunal (NCLT), Ahmedabad Bench, sanctioned the Scheme of Amalgamation on July 6, 2026.
- July 17, 2026, was designated as the record date for shareholders to receive 51 Torrent Pharmaceuticals shares for every 100 J. B. Chemicals shares.
- J. B. Chemicals filed its compliance certificate for SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2026, on July 7, 2026.

### Official Filings

J. B. Chemicals & Pharmaceuticals Limited has undergone a significant corporate restructuring, culminating in its amalgamation with and dissolution into Torrent Pharmaceuticals Limited. This process was formally completed on July 8, 2026, following the National Company Law Tribunal's (NCLT) sanction of the Scheme of Amalgamation on July 6, 2026, with the certified order received on July 7, 2026. The effective date for this amalgamation was January 21, 2026. As part of this scheme, shareholders of J. B. Chemicals & Pharmaceuticals Limited are entitled to receive shares of Torrent Pharmaceuticals Limited. The record date for determining these entitlements was set as July 17, 2026. Shareholders will receive 51 Torrent Pharmaceuticals Limited shares for every 100 J. B. Chemicals & Pharmaceuticals Limited shares held. Separately, the company confirmed compliance with SEBI regulations regarding the dematerialization of securities for the quarter ended June 30, 2026. Earlier, on June 17, 2026, shareholders approved all resolutions at the 50th Annual General Meeting, including financial statements for the year ended March 31, 2026, and dividends. The company also disclosed the retirement of two senior management personnel effective June 30, 2026, and the resignation of an Executive Vice President – Supply Chain Management effective June 12, 2026.

- Amalgamation of J. B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited completed on July 8, 2026.
- Torrent Pharmaceuticals Limited shares exchange ratio: 51 shares for every 100 J. B. Chemicals & Pharmaceuticals Limited shares held.
- Record date for share entitlement was July 17, 2026.
- Shareholders approved financial statements and dividends at the 50th AGM on June 17, 2026.
- Two senior management personnel retired effective June 30, 2026; one Executive Vice President resigned effective June 12, 2026.

### Fundamentals

J.B. Chemicals & Pharmaceuticals reported revenue from operations of ₹1,084.90 crore in Q2 FY2025-26, which slightly decreased to ₹1,064.72 crore in Q3 FY2025-26 and further to ₹904.23 crore in Q4 FY2025-26. Profit Before Exceptional Items And Tax followed a similar trend, declining from ₹279.15 crore in Q2 FY2025-26 to ₹266.87 crore in Q3 FY2025-26, and significantly dropping to ₹161.87 crore in Q4 FY2025-26. The company recorded an exceptional item expense of ₹27.18 crore in Q4 FY2025-26, which contributed to a lower Profit Before Tax of ₹134.69 crore for that quarter, compared to ₹279.15 crore in Q2 FY2025-26 and ₹266.87 crore in Q3 FY2025-26. Finance costs remained relatively stable across the periods, with Q4 FY2025-26 showing ₹1.23 crore. Other expenses also fluctuated, standing at ₹241.55 crore in Q2 FY2025-26, ₹248.05 crore in Q3 FY2025-26, and ₹230.12 crore in Q4 FY2025-26.

Key monitoring areas include the sequential decline in revenue and profitability, particularly the impact of exceptional items in the latest reported quarter. Investors may wish to observe the company's ability to stabilize and grow its revenue and profit margins in upcoming periods, as well as the nature and recurrence of any exceptional items impacting earnings.

- Revenue from operations for J.B. Chemicals & Pharmaceuticals was ₹1,084.90 crore in Q2 FY2025-26, ₹1,064.72 crore in Q3 FY2025-26, and ₹904.23 crore in Q4 FY2025-26.
- Profit Before Exceptional Items And Tax decreased from ₹279.15 crore in Q2 FY2025-26 to ₹161.87 crore in Q4 FY2025-26.
- An exceptional item expense of ₹27.18 crore was recorded in Q4 FY2025-26, leading to a Profit Before Tax of ₹134.69 crore for the quarter.
- Finance costs were ₹1.35 crore in Q2 FY2025-26, ₹1.88 crore in Q3 FY2025-26, and ₹1.23 crore in Q4 FY2025-26.
- Other expenses were ₹241.55 crore in Q2 FY2025-26, ₹248.05 crore in Q3 FY2025-26, and ₹230.12 crore in Q4 FY2025-26.

### Bull Case

J.B. Chemicals & Pharmaceuticals (NSE) is exhibiting strength across multiple technical timeframes as of September 18, 2026. The daily trend shows a bullish Super Trend indicator at ₹2,316.94, with the closing price of ₹2,408.90 trading above both the 20-day Exponential Moving Average (EMA) of ₹2,370.39 and the 50-day EMA of ₹2,265.55. The slopes of these EMAs and Simple Moving Averages (SMAs) are also positive, indicating upward momentum. This bullish sentiment extends to the weekly and monthly charts, which also show a bullish Super Trend direction, suggesting sustained positive momentum. The stock has also delivered a notable return of 42% over the past year, and 32% year-to-date, indicating strong performance over these periods.

- The daily Super Trend indicator is bullish as of September 18, 2026, with a value of ₹2,316.94.
- The closing price of ₹2,408.90 on September 18, 2026, is above the 20-day EMA (₹2,370.39) and 50-day EMA (₹2,265.55).
- Positive slopes on daily EMAs and SMAs indicate upward momentum.
- Weekly and monthly trends also show a bullish Super Trend direction.
- The stock has achieved a 42% return over the past year and a 32% year-to-date return.

### Bear Case

The company's stock is trading near its nearest resistance level of ₹2438.13, which is 1.21% above the current price of ₹2408.9. While the stock has shown a positive return of 42% over the past year, its current drawdown stands at -4%. The Average Directional Index (ADX) on a daily timeframe is 40.25, indicating strong trend momentum, but a high ADX can also signal an overextended move. The stock's current price is above its 20-day Exponential Moving Average (EMA) of ₹2370.39 and its 50-day EMA of ₹2265.55, suggesting short-term upward momentum. However, the Average True Range (ATR) at 2.74% indicates a notable level of volatility.

- The stock is trading at ₹2408.9 as of 2026-09-18, with the nearest pivot resistance level identified at ₹2438.13.
- The current drawdown is -4%, indicating a recent dip from a previous high.
- The daily ADX reading of 40.25 suggests a strong trend, which could imply potential for a reversal if the trend is overextended.
- The Average True Range (ATR) is 2.74%, highlighting the stock's volatility.

### FAQs

**What is the current status of J.B. Chemicals & Pharmaceuticals Limited following its amalgamation?**

J.B. Chemicals & Pharmaceuticals Limited was amalgamated with and dissolved into Torrent Pharmaceuticals Limited, effective from January 21, 2026. The National Company Law Tribunal (NCLT) sanctioned the Scheme of Amalgamation on July 6, 2026, with the certified order received on July 7, 2026. The amalgamation was officially filed with the Registrar of Companies, Ahmedabad, on July 8, 2026. Shareholders were entitled to receive 51 Torrent Pharmaceuticals Limited shares for every 100 J.B. Chemicals & Pharmaceuticals Limited shares held, with July 17, 2026, set as the record date for this entitlement.

**What were the recent stock performance trends for J.B. Chemicals & Pharmaceuticals Limited prior to its amalgamation?**

As of September 18, 2026, J.B. Chemicals & Pharmaceuticals Limited's stock exhibited a bullish trend across daily, weekly, and monthly timeframes, based on technical indicators such as the Supertrend and moving average slopes. The stock had a year-to-date return of 32% and a one-year return of 42%. However, the stock also showed a current drawdown of -4% and a maximum drawdown of -21% over its history, with annualized volatility at 25%.

**What are the key support and resistance levels for J.B. Chemicals & Pharmaceuticals Limited as of September 18, 2026?**

As of September 18, 2026, key technical levels for J.B. Chemicals & Pharmaceuticals Limited included support at ₹2386.80 (0.92% below the current price) and resistance at ₹2438.13 (1.21% above the current price), based on pivot points. Further resistance levels were identified at ₹2496.27 and ₹2583.63.
## Technical analytics

- As of: 2026-07-15
- Daily trend: Strong Uptrend
- Weekly trend: Insufficient History
- Pivot point: ₹2,438.13
- Risk regime: Price Risk Currently Contained

### Support levels
- 2386.8
- 2076.825
- 2019.5

### Resistance levels
- 2496.2666666666664
- 2583.633333333333
- 2641.7666666666664

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +0.00% |
| return_10 | +1.87% |
| return_1m | +0.00% |
| return_1y | +42.47% |
| return_20 | +9.57% |
| return_3m | +9.57% |
| return_5 | -1.09% |
| return_6m | +13.73% |
| return_since_start | +28.26% |
| return_ytd | +32.36% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | contained_risk |
| label | Price risk currently contained |
| summary | Recent drawdown and price variability remain within the producer's contained-risk thresholds. |
| maximum_drawdown | -20.67% |
| annualized_volatility | +25.43% |

## Quarterly financials

- Latest complete quarter: fy26_q4

# Revenue and Profitability Contract as Expenses Outpace Sales Decline

J.B. Chemicals & Pharmaceuticals reported a contraction in both sales and earnings for the quarter ended March 2026. Revenue fell 4.8% compared to the same period last year and dropped 15.1% from the preceding quarter. Profit before tax declined more sharply, falling 30.2% year-on-year and 49.5% sequentially, driven by a slower reduction in operating costs and a reported exceptional charge.

## Revenue and Profitability Trends

Revenue from operations totaled ₹904.23 crore in the fourth quarter, down from ₹949.48 crore a year earlier and ₹1,064.72 crore in the third quarter. Over the fiscal year, sales peaked at ₹1,093.94 crore in the first quarter and trended downward through the second and third quarters before the steeper decline in the final quarter.

Profit before exceptional items and tax (PBEIT) followed a similar path, settling at ₹161.87 crore. This represents a 16.1% decrease from the prior-year quarter and a 39.3% drop from the previous quarter. As a percentage of revenue, PBEIT margin compressed from 20.3% a year ago and 25.1% in the third quarter to 17.9% in the current quarter. The wider drop in profit compared to revenue indicates that operating costs did not scale down proportionally with the sales decline.

## Impact of Exceptional Items

Pre-tax profit (PBT) closed at ₹134.69 crore, reflecting a 30.2% year-on-year decline and a 49.5% sequential fall. The reported results include an exceptional item before tax of –₹27.18 crore for the quarter, which was not present in the four preceding quarters. This charge accounted for roughly one-fifth of the sequential drop in pre-tax profit, with the remainder stemming from the lower underlying operating profitability.

## Expense Composition

Total operating expenses came to ₹754.34 crore, a 2.2% decrease year-on-year and a 7.6% decrease from the third quarter. While expenses declined, the pace of reduction lagged behind the double-digit sequential drop in revenue.

Key expense components for the quarter include:
- Cost of materials consumed: ₹233.71 crore
- Purchases of stock-in-trade: ₹102.82 crore
- Change in inventories: –₹62.28 crore
- Employee benefit expense: ₹198.73 crore
- Depreciation, depletion, and amortisation: ₹50.01 crore
- Finance costs: ₹1.23 crore
- Other expenses: ₹230.12 crore

Employee benefits and other expenses combined made up 56.8% of total costs. Both categories showed limited responsiveness to the revenue contraction; other expenses actually rose 2.5% year-on-year to ₹230.12 crore despite lower sales.

## Capital Structure

Paid-up equity share capital increased to ₹16.06 crore at the end of the quarter, up from ₹15.57 crore a year earlier. The face value of shares remained unchanged at ₹1 per share.

## Key Takeaway

The quarter concluded with a notable pullback in sales and earnings. Profitability contracted more steeply than revenue because operating expenses, particularly employee costs and general overheads, decreased at a slower rate. An additional exceptional charge further weighed on pre-tax results. The performance marks a clear deceleration from the higher revenue and profit levels recorded in the first three quarters of the fiscal year.

### Ratios

## Official filings

- 2026-07-08 — Generic Announcement: On July 8, 2026, J. B. Chemicals & Pharmaceuticals Limited (JB Chemicals) was amalgamated with and dissolved into Torrent Pharmaceuticals Limited, effective from the Appointed Date of January 21, 2026. This follows the approval and sanction of the Scheme of Amalgamation by the National Company Law Tribunal (NCLT) on July 6, 2026, with the certified order received on July 7, 2026. The certified copies of the order and scheme were filed with the Registrar of Companies, Ahmedabad, on July 8, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_08072026113021_JB_SE_Intimation_Effective_Date.pdf)
- 2026-07-07 — Generic Announcement: J. B. Chemicals & Pharmaceuticals Limited has fixed July 17, 2026, as the record date to determine shareholders entitled to receive Torrent Pharmaceuticals Limited shares as per the approved amalgamation scheme. Shareholders will receive 51 Torrent Pharma shares for every 100 J. B. Chemicals shares held, with Torrent Pharma shares having a face value of Rs. 5 each and J. B. Chemicals shares having a face value of Re. 1 each. This follows the National Company Law Tribunal's order dated July 6, 2026, sanctioning the amalgamation. — [Official attachment](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_07072026195932_SE_intimation_Record_date_for_Amalgamation.pdf)
- 2026-07-07 — Generic Announcement: The National Company Law Tribunal, Ahmedabad Bench, sanctioned the Scheme of Amalgamation of J. B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited on July 6, 2026. J. B. Chemicals & Pharmaceuticals Limited received the certified true copy of this order on July 7, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_07072026180222_SE_Intimation_Certified_copy_of_Order.pdf)
- 2026-07-07 — Generic Announcement: J.B. Chemicals & Pharmaceuticals Limited received a certificate from its Registrar and Share Transfer Agents, Datamatics Business Solutions Limited, confirming compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. This certificate covers the quarter ended June 30, 2026, and verifies that securities received for dematerialization were mutilated, cancelled, and replaced with the depository as the registered owner within 15 days of receipt. — [Official attachment](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_07072026211912_SE_Intimation_Quarterly_Reg_74.pdf)
- 2026-07-06 — Generic Announcement: The Hon'ble National Company Law Tribunal, Ahmedabad Bench, has sanctioned the Scheme of Amalgamation of J. B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited. The sanction was granted via an order dated July 6, 2026. The Scheme will become effective upon filing the certified copy of the order with the Registrar of Companies. — [Official attachment](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_06072026184738_SE_Intimation_Pronuncement_of_Order_v1.pdf)
- 2026-06-30 — Generic Announcement: J.B. Chemicals & Pharmaceuticals Limited announced the retirement of two senior management personnel, Mr. Pradeep Kumar Singh (President Global Business) and Mr. Suresh Bhise (Vice President – IT), effective June 30, 2026. This disclosure is made in accordance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. — [Official attachment](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_30062026180436_NSE_retirement30062026.pdf)
- 2026-06-30 — Generic Announcement: J.B. Chemicals & Pharmaceuticals Limited will close its trading window from July 1, 2026, until 48 hours after the declaration of its unaudited financial results for the quarter ending June 30, 2026. This closure is in accordance with SEBI (Prohibition of Insider Trading) Regulations. — [Official attachment](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_30062026182058_NSE_TW30062026.pdf)
- 2026-06-17 — Generic Announcement: J.B. Chemicals & Pharmaceuticals Limited held its 50th Annual General Meeting on June 17, 2026, through video conference. All resolutions, including the adoption of financial statements for the year ended March 31, 2026, confirmation of an interim dividend of Rs. 12.70 per share, declaration of a final dividend of Rs. 9.30 per share, and the re-appointment of Mr. Amal Kelshikar as a director, were approved by the shareholders with a significant majority. The voting results were based on consolidated reports from the appointed scrutinizer. — [Official attachment](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_17062026202753_Voting_Result_with_Scrutinizer_Report_Signed.pdf)
- 2026-06-17 — Generic Announcement: The 50th Annual General Meeting of J. B. Chemicals & Pharmaceuticals Limited was held on June 17, 2026, via Video Conference. The meeting addressed four ordinary resolutions, and members participated through remote e-voting and an e-voting platform provided by CDSL. The Statutory Auditors' and Secretarial Audit Reports contained no adverse qualifications. The meeting concluded at 3:55 PM IST, with voting results to be announced separately. — [Official attachment](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_17062026201352_Stock_exchange_proceeding.pdf)
- 2026-06-15 — Generic Announcement: J.B. Chemicals & Pharmaceuticals Limited announced that Mr. Bhushan Sachdev has resigned from his position as Executive Vice President – Supply Chain Management due to personal reasons, effective June 12, 2026. This disclosure is made in compliance with SEBI regulations. — [Official attachment](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_15062026175443_NSE_Bhushan_resignation_with_reason.pdf)
- 2026-06-13 — Generic Announcement: J.B. Chemicals & Pharmaceuticals Limited submitted audited standalone and consolidated financial results for the fiscal year ended March 31, 2026, on May 11, 2026. The Board of Directors approved these results and authorized Director Mr. Sudhir Menon to sign them for submission to the stock exchanges. This clarification was provided in response to an email from the National Stock Exchange of India Limited dated May 20, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_21052026175045_Reply_to_NSE.pdf)
- 2026-06-12 — Management Change: Mr. Bhushan Sachdev has resigned as Executive Vice President – Supply Chain Management for J.B. Chemicals & Pharmaceuticals Limited, effective June 12, 2026. This disclosure is made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. — [Official attachment](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_12062026181112_NSEIntimationCessationofSMP.pdf)
- 2026-05-27 — Generic Announcement: J.B. Chemicals & Pharmaceuticals Limited dispatched letters on May 27, 2026, providing a web-link to access its Integrated Annual Report for FY 2025-26 to shareholders who have not registered their email addresses. The company also announced its 50th Annual General Meeting (AGM) scheduled for June 17, 2026, to be held via Video Conference (VC) / Other Audio-Visual Means (OAVM). The Notice of the 50th AGM and the Integrated Annual Report for FY 2025-26 were sent electronically to members with registered email addresses. — [Official attachment](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_27052026183403_NSE_Weblink25062026.pdf)
- 2026-05-26 — Generic Announcement: J.B. Chemicals & Pharmaceuticals Limited published a notice on May 26, 2026, regarding its Annual General Meeting scheduled for June 17, 2026. The meeting will be conducted via Video Conferencing (VC)/Other Audio Visual Means (OAVM), in compliance with SEBI regulations. — [Official attachment](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_26052026203843_NSE_newspaper_26052026.pdf)
- 2026-05-25 — Generic Announcement: J. B. Chemicals & Pharmaceuticals Limited will hold its 50th Annual General Meeting on June 17, 2026, via video conference. The agenda includes adopting financial statements for the year ended March 31, 2026, confirming an interim dividend of ₹12.70 per equity share, declaring a final dividend of ₹9.30 per equity share for the 2025-26 financial year, and re-appointing Mr. Amal Kelshikar as a director retiring by rotation. — [Official attachment](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_25052026170303_NSE_Notice2026.pdf)
- 2026-05-25 — Generic Announcement: J.B. Chemicals & Pharmaceuticals Limited has submitted its Business Responsibility and Sustainability Report for the financial year 2025-26, as required by SEBI regulations. The report details the company's performance and commitments across environmental, social, and governance (ESG) pillars. Key disclosures include operational data, employee welfare initiatives, and progress towards sustainability goals such as renewable energy adoption and carbon neutrality targets. — [Official attachment](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_25052026183655_NSE_BRSR2026.pdf)
- 2026-05-21 — Generic Announcement: J.B. Chemicals & Pharmaceuticals Limited has fixed May 29, 2026, as the record date to determine shareholder eligibility for the final dividend for the financial year 2025-26. This action is in accordance with Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. — [Official attachment](https://nsearchives.nseindia.com/corporate/JBCHEPHARM_21052026183424_NSE_RecordDate.pdf)
- 2026-05-20 — Official Filing: J.B. Chemicals & Pharmaceuticals Limited will convene its Annual General Meeting on June 17, 2026, utilizing Video Conferencing (VC)/Other Audio Visual Means (OAVM). This disclosure, made on May 20, 2026, precedes the dispatch of the official AGM notice and the 2025-26 annual report to shareholders, adhering to Ministry of Corporate Affairs guidelines.
- 2026-05-13 — Official Filing: J.B. Chemicals & Pharmaceuticals Limited held an Investors/Analysts call on May 12, 2026, to discuss results for the fourth quarter ended March 31, 2026. The company reported revenue of INR904 crores, a 5% decrease, with INR40 crores in one-off charges. Adjusted EBITDA was flat at INR241 crores, and reported net profit after tax was INR101 crores, or INR150 crores adjusted for one-offs. The Board recommended a final dividend of INR9.3 per equity share. The merger with Torrent Pharma is in its final stages, with a hearing expected in June 2026.
- 2026-05-12 — Official Filing: J.B. Chemicals & Pharmaceuticals Limited published a newspaper advertisement on May 12, 2026, detailing its financial results for the quarter and financial year ended March 31, 2026. This disclosure was made in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 2026-05-12 — Official Filing: J.B. Chemicals & Pharmaceuticals Limited has made available the audio recording of an investor and analyst conference call held on May 12, 2026. The call pertained to the company's results and developments for the fourth quarter ended March 31, 2026. The recording is accessible on the company's website.
- 2026-05-11 — Official Filing: On May 11, 2026, J.B. Chemicals & Pharmaceuticals Limited disclosed that a company petition for the Scheme of Amalgamation with Torrent Pharmaceuticals Limited was admitted by the National Company Law Tribunal on May 7, 2026. The hearing for this petition is scheduled for June 11, 2026. Newspaper advertisements regarding this notice were published on May 11, 2026.
- 2026-05-11 — Official Filing: J.B. Chemicals & Pharmaceuticals Ltd. reported Q4 FY26 results with revenue at Rs. 904 crores and EBITDA at Rs. 241 crores, a 5% YoY decrease in revenue. The company experienced a net profit after tax of Rs. 101 crores, down 30% YoY. Performance was impacted by integration activities following a change of control, including distribution network optimization, discontinuation of low-margin products, and alignment of practices with the parent entity, affecting both domestic and international business segments. The company anticipates progressive performance improvement starting in Q1 FY27.
- 2026-05-11 — Official Filing: The Board of Directors of J.B. Chemicals & Pharmaceuticals Ltd. recommended a final dividend of Rs. 9.30 per equity share (930%) for the financial year 2025-26. This recommendation was made during a board meeting held on May 11, 2026. The dividend, if approved by shareholders at the Annual General Meeting, will be paid within 30 days of its declaration.
- 2026-05-11 — Official Filing: J. B. Chemicals & Pharmaceuticals Ltd. announced the audited standalone and consolidated financial results for the fiscal year ended March 31, 2026. The Board of Directors approved these results, which include an unmodified audit opinion from Deloitte Haskins & Sells LLP. The company also reported related party transactions for the half-year ending March 31, 2026. The proposed amalgamation scheme with Torrent Pharmaceuticals Limited received approval from shareholders on April 28, 2026, with an appointed date of January 21, 2026.

## News and market events

No recent news or market events are currently available.

## Business profile

**Strategic vision:** Manufactures and markets diverse pharmaceutical products globally.

### Business segments
- **Pharmaceutical Manufacturing and Marketing:** Engaged in the manufacturing and marketing of a diverse range of pharmaceutical products, including generic and branded generics across various therapeutic categories.

### Competitive strengths
- Extensive global distribution network across over 40 countries.
- Multiple world-class manufacturing facilities with numerous international accreditations.
- Broad therapeutic area coverage and diverse product dosage forms.

## Related stocks

- [360ONE (Financial Services)](https://faxioms.com/stocks/360one) — +1.96%
- [3MINDIA (Diversified)](https://faxioms.com/stocks/3mindia) — +5.50%
- [AADHARHFC](https://faxioms.com/stocks/aadharhfc) — -1.42%
- [AARTIIND](https://faxioms.com/stocks/aartiind) — +3.19%
- [AAVAS](https://faxioms.com/stocks/aavas) — -1.07%

## Freshness and sources

- Data as of: 2026-07-15
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/jbchepharm
Markdown representation: https://faxioms.com/stocks/jbchepharm?render=md